NDATOPICALAEROSOL, FOAM
Approved
Feb 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
LUXIQ (betamethasone valerate) by Merck & Co. is clinical pharmacology: topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. First approved in 1999.
Drug data last refreshed 3d ago
Mechanism of Action
CLINICAL PHARMACOLOGY: Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LUXIQ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.